Frontiers in cellular neuroscience · 2026
Efficacy of anticoagulation therapy in elderly patients with clinically diagnosed Alzheimer's disease and atrial fibrillation: a clinical outcomes study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Xinhui, Yang Xinying, Huang Yiman, Qian Peng, Duan Hongyan
Аннотация
INTRODUCTION: Clinically diagnosed Alzheimer's disease (AD) and atrial fibrillation (AF) are prevalent in the elderly, and their co-occurrence presents a complex management dilemma, balancing stroke prevention against bleeding risks, particularly in the context of cognitive impairment. This real-world cohort study aimed to evaluate the clinical outcomes of anticoagulant therapy in elderly patients with AD and AF.
METHODS: We analyzed data from 342 patients (mean age 78.5 years; 58.3% female) with non-valvular AF and AD. Patients were categorized into anticoagulant (n = 247; 72.2%) and non-anticoagulant (n = 95; 27.8%) groups, with direct oral anticoagulants (DOACs) used in 57.9% of treated patients. Over a mean follow-up of 2.1 years, outcomes were compared between groups.
RESULTS: Anticoagulation was associated with a significantly lower incidence of ischemic stroke/systemic embolism (annualized rate 2.9% vs. 7.1%; hazard ratio [HR] = 0.35, 95% CI 0.17-0.73, p = 0.005) and all-cause mortality (6.3% vs. 15.1%; HR = 0.32, 95% CI 0.19-0.54, p < 0.001) compared to no anticoagulation. DOACs were superior to warfarin in preventing stroke/embolism (HR = 0.36, 95% CI 0.15-0.87, p = 0.022). While major bleeding was higher with anticoagulation (6.1% vs. 0.9%; HR = 4.31, 95% CI 1.02-18.19, p = 0.047), the critical risk of intracranial hemorrhage was not significantly increased (1.6% vs. 1.0%; HR = 0.46, 95% CI 0.11-1.98, p = 0.30), and DOACs demonstrated a safer profile versus warfarin for major bleeding (HR = 0.24, 95% CI 0.06-0.89, p = 0.034). Key predictors for bleeding and thromboembolism, for example, advanced age, previous stroke history, and high HAS-BLED scores, were identified.
DISCUSSION: In conclusion, anticoagulation, particularly with DOACs, provides a favorable net clinical benefit by significantly reducing stroke and mortality without a marked increase in intracranial hemorrhage in elderly AD patients with AF, supporting its judicious use. Further prospective studies are warranted to refine personalized decision-making.
SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251271276, Identifier: CRD420251271276.
METHODS: We analyzed data from 342 patients (mean age 78.5 years; 58.3% female) with non-valvular AF and AD. Patients were categorized into anticoagulant (n = 247; 72.2%) and non-anticoagulant (n = 95; 27.8%) groups, with direct oral anticoagulants (DOACs) used in 57.9% of treated patients. Over a mean follow-up of 2.1 years, outcomes were compared between groups.
RESULTS: Anticoagulation was associated with a significantly lower incidence of ischemic stroke/systemic embolism (annualized rate 2.9% vs. 7.1%; hazard ratio [HR] = 0.35, 95% CI 0.17-0.73, p = 0.005) and all-cause mortality (6.3% vs. 15.1%; HR = 0.32, 95% CI 0.19-0.54, p < 0.001) compared to no anticoagulation. DOACs were superior to warfarin in preventing stroke/embolism (HR = 0.36, 95% CI 0.15-0.87, p = 0.022). While major bleeding was higher with anticoagulation (6.1% vs. 0.9%; HR = 4.31, 95% CI 1.02-18.19, p = 0.047), the critical risk of intracranial hemorrhage was not significantly increased (1.6% vs. 1.0%; HR = 0.46, 95% CI 0.11-1.98, p = 0.30), and DOACs demonstrated a safer profile versus warfarin for major bleeding (HR = 0.24, 95% CI 0.06-0.89, p = 0.034). Key predictors for bleeding and thromboembolism, for example, advanced age, previous stroke history, and high HAS-BLED scores, were identified.
DISCUSSION: In conclusion, anticoagulation, particularly with DOACs, provides a favorable net clinical benefit by significantly reducing stroke and mortality without a marked increase in intracranial hemorrhage in elderly AD patients with AF, supporting its judicious use. Further prospective studies are warranted to refine personalized decision-making.
SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251271276, Identifier: CRD420251271276.